Hamilton city council unanimously opposes plan by the CBS and Spanish pharmaceutical company as health advocates share concerns about exploitation of donors
Availability of GLASSIA® represents significant milestone for patients with emphysema due to severe hereditary deficiency of Alpha-1 antitrypsin TORONTO, Dec. 20, 2023 /CNW/ - Takeda Canada Inc. (Takeda) has
An Edmonton woman is calling on the Alberta government to again cover the costs of a medical treatment that could prolong her life so she doesn’t have to move…
An Edmonton woman is calling on the Alberta government to again cover the costs of a medical treatment that could prolong her life so she doesn’t have to move…
Agility PR Solutions: Campaign Launched for Life-Sustaining Treatment Access Across Canada
Toronto, Ontario (Newsfile Corp. - May 31, 2021) -
Alpha-1 Canada publicly launched Access for Alphas today, a campaign aimed at raising the awareness of alpha-1 antitrypsin deficiency (AATD) with provincial elected officials to approve an augmentation therapy category on the Canadian Blood Services Plasma Protein and Related Products Formulary for Canadians across the country with this progressive genetic disease. For decades alpha-1 patients have suffered silently without being able to access life-sustaining therapy. That ends today with the launch of Access for Alphas, which aims to finally get provinces to approve the addition of augmentation therapy within Canadian Blood Services, so that hundreds of Canadians can access this vital treatment, began Angela Diano, Executive Director of Alpha-1 Canada.